Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models

Prostate

Volumn 59, Issue 1, 2004, Pages 22-32

  Van Laar, Emily S ^a   Weitman, Steven ^b   MacDonald, John R ^a   Waters, Stephen J ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

DU 145; HMAF; PC 3; Preclinical

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; DOCETAXEL; IMMUNEX; IROFULVEN; MITOXANTRONE;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, NUDE; MITOXANTRONE; PROSTATIC NEOPLASMS; SESQUITERPENES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1642308705     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10351     Document Type: Article

References (61)

1. Woynarowska BA, Woynarowski JM, Herzig MC, Roberts K, Higdon AL, MacDonald JR. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 2000;59: 1217-1226.
2. MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997;57: 279-283.
3. Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 1996;14:161-167.
4. Sato Y, Kashimoto S, MacDonald JR, Nakano K. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur J Cancer 2001;37: 1419-1428.
5. Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res 2000;154:429-438.
6. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 1999;59: 1049-1053.
7. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer 2000;36:2430-2436.
8. Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Estes L. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol 2002;49:412-418.
9. Kelner MJ, McMorris TC, Beck WT, Zamora JM, Taetle R. Preclinical evaluation of illudins as anticancer agents. Cancer Res 1987;47:3186-3189.
10. Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochem Biophys Acta 2002;1587:309-317.
11. Liang H, Munoz RM, Higdon A, Waters SJ, Woynarowska BA. Early events in apoptosis induced by irofulven (hydroxymethylacylfulvene) in prostate tumor cells. Proc Am Assoc Cancer Res 2001;42(3445):640.
12. Kelner MJ, McMorris TC, Estes LA, Oval MY, Rojas RJ, Lynn JR, Lanham KA, Samson KM. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs 2000;11:217-224.
13. Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 1998;34:908-913.
14. Herzig MC, Trevino A, Liang H, Salinas R, Waters SJ, MacDonald JR, Woynarowska BA, Woynarowski JM. Apoptosis induction by the novel antitumor agent irofulven is largely Bcl-2-independent. Biochem Pharmacol 2002;65:503-513.
15. Izbicka E, Davidson K, Lawrence R, Cote R, MacDonald JR, Von Hoff DD. Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res 1999;19: 1299-1307.
16. Woynarowski JM, Napier C, Koester SK, Chen SF, Troyer D, Chapman W, MacDonald JR. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997;54:1181-1193.
17. Kelner MJ, McMorris TC, Estes L, Rutherford M, Montoya M, Goldstein J, Samson K, Starr R, Taetle R. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 1994;48:403-409.
18. Jaspers NGJ, Raams A, Kelner MJ, Ng JMY, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JHJ. Antitumor compounds illudin S and irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription and replication-coupled repair pathways. DNA Repair 2002;1: 1027-1038.
19. Takebayashi Y, Nakayama K, Kanzaki A, Miyashita H, Ogura O, Mori S, Mutoh M, Miyazaki K, Fukumoto M, Pommier Y. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon, and lung carcinomas: Implication for their roles of carcinogenesis in human solid tumors. Cancer Lett 2001;174:115-125.
20. Chang LC, Sheu HM, Huang YS, Kuo KW. Quantitative determination of the expression of xeroderma pigmentosum F gene in human nonmelanoma skin cancers. Biochem Biophys Res Commun 2000;273:454-458.
21. Hyytinen ER, Frierson HF Jr., Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT. Loss of heterozygosity and lack of mutations of the XPG/ ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate 1999;41:190-195.
22. Sarosy GA, Kotz H, Smith S, Murgo A, Minasian L, Dyer V, Kohler D, Kim S, Reed E. Phase II study of irofulven in platinum resistant recurrent ovarian cancer. Proc Am Soc Clin Oncol 2001;20(868):218a.
23. Culine S, Tombal B, Pozzo C, Tourani JM, Fizazi K, Merad Z, Benoit G, Eymard JC, Ould Kaci M, Weems G, Blakolmer K, Cvitkovic E. Randomized phase II trial of irofulven with or without prednisone in hormone-refractory prostate cancer (HRPC) patients (pts): Preliminary results. Proc Am Soc Clin Oncol 2002;21(2462):161b.
24. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: Current and future approaches. Drugs 2001;61: 2177-2192.
25. de la Taille A, Vacherot F, Salomon L, Druel C, Gil Diez de Medina S, Abbou C, Buttyan R, Chopin D. Hormone-refractory prostate cancer: A multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001;4:204-212.
26. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002;7:360-370.
27. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
28. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-1663.
29. Mitoxantrone: New indication. More risky than beneficial in advanced prostate cancer. Prescrire Int 2001;10:110-112.
30. Friedland D, Cohen J, Miller R Jr., Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26:19-23.
31. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 1999;26:14-18.
32. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279.
33. Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Velasco TR, Estes L, Suthipinijtham P. Enhanced antitumor activity of Irofulven in combination with antimitotic agents. Invest New Drugs 2002; 20:271-279.
34. Weitman SD, Smith S, Eder J, Tempero MA, Eckhardt SG, Reed E, Gordon A, Senzer N, Raymond E, Alexandre J, Ould Kaci M, MacDonald J. Irofulven monotherapy: Impressive phase I and II clinical antitumor activity in heavily treated patients. Proc Am Soc Clin Oncol 2001;20(2081):83b.
35. Raymond E, Ady-Vago N, Ould Kaci M, Alexandre J, Faivre S, Brain E, Armand JP, Smith S, Weems G, Cvitkovic E, Misset JL. Phase I study of irofulven (MGI 114) given weekly (D1-D8) as A 5′ infusion every 3 weeks (W): Preliminary results. Proc Am Soc Clin Oncol 2001;20(2084):84b.
36. Alexandre J, Kahatt C, Ould Kaci M, Raymond E, Brain E, Smith S, Lagree S, Vanderbilt K, Cvitkovic E, Misset JL. Phase I study of irofulven (MGI 114) given as A 5′ infusion once every 2 weeks (W): Preliminary results. Proc Am Soc Clin Oncol 2001; 20(2083):83b.
37. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994;50:834-841.
38. Greco WR, Bravo G, Parsons JC. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 2001;47:331-385.
39. Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H. Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemother Pharmacol 2001;48:467-472.
40. Devi GR. Prostate cancer: Status of current treatments and emerging antisense-based therapies. Curr Opin Mol Ther 2002;4: 138-148.
41. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992;20:281-295.
42. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999;35:664-671.
43. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-134.
44. Tang DG, Li L, Chopra DP, Porter AT. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998;58:3466-3479.
45. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol 1999;26:185-191.
46. Kelner MJ, McMorris TC. Irofulven is synergistic with multiple chemotherapeutic agents. Proc Am Assoc Cancer Res 2002; 43(304):60.
47. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990;50:5813-5818.
48. Suciu D. Inhibition of DNA synthesis and cytotoxic effects of some DNA topoisomerase II and gyrase inhibitors in Chinese hamster V79 cells. Mutat Res 1990;243:213-218.
49. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-235.
50. Catapano CV, Carbone GM, Pisani F, Qiu J, Fernandes DJ. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. Biochemistry 1997;36:5739-5748.
51. Hong G, Kreuzer KN. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo. Mol Cell Biol 2000;20:594-603.
52. Kim DK, Baek JH, Kang CM, Yoo MA, Sung JW, Chung HY, Kim ND, Choi YH, Lee SH, Kim KW. Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int J Cancer 2000;87:629-636.
53. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983;10:3-11.
54. Duguet M. When helicase and topoisomerase meet! J Cell Sci 1997;110:1345-1350.
55. Mondal N, Parvin JD. DNA topoisomerase II alpha is required for RNA polymerase II transcription on chromatin templates. Nature 2001;413:435-438.
56. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 1996;13:823-831.
57. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3-7.
58. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Huntingt) 2002;16:63-72.
59. Herzig MC, Liang H, Johnson AE, Woynarowska B, Woynarowski JM. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast Cancer Res Treat 2002;71:133-143.
60. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999;44: 355-361.
61. Kolfschoten GM, Hulscher TM, Duyndam MC, Pinedo HM, Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 2002;63:733-743.